PL2799070T3 - Środek wzmacniający działanie środków przeciwnowotworowych - Google Patents
Środek wzmacniający działanie środków przeciwnowotworowychInfo
- Publication number
- PL2799070T3 PL2799070T3 PL12863476T PL12863476T PL2799070T3 PL 2799070 T3 PL2799070 T3 PL 2799070T3 PL 12863476 T PL12863476 T PL 12863476T PL 12863476 T PL12863476 T PL 12863476T PL 2799070 T3 PL2799070 T3 PL 2799070T3
- Authority
- PL
- Poland
- Prior art keywords
- antitumor agents
- effect potentiator
- potentiator
- effect
- antitumor
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011290125 | 2011-12-28 | ||
| PCT/JP2012/083794 WO2013100014A1 (ja) | 2011-12-28 | 2012-12-27 | 抗腫瘍剤の効果増強剤 |
| EP12863476.3A EP2799070B1 (en) | 2011-12-28 | 2012-12-27 | Effect potentiator for antitumor agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2799070T3 true PL2799070T3 (pl) | 2019-07-31 |
Family
ID=48697493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12863476T PL2799070T3 (pl) | 2011-12-28 | 2012-12-27 | Środek wzmacniający działanie środków przeciwnowotworowych |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20140378409A1 (pl) |
| EP (1) | EP2799070B1 (pl) |
| JP (1) | JP5852678B2 (pl) |
| KR (1) | KR101668931B1 (pl) |
| AU (2) | AU2012361581B2 (pl) |
| DK (1) | DK2799070T3 (pl) |
| ES (1) | ES2717898T3 (pl) |
| HU (1) | HUE043991T2 (pl) |
| PL (1) | PL2799070T3 (pl) |
| PT (1) | PT2799070T (pl) |
| RU (1) | RU2589713C2 (pl) |
| TW (1) | TWI594986B (pl) |
| WO (1) | WO2013100014A1 (pl) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6161705B2 (ja) | 2013-08-22 | 2017-07-12 | 大鵬薬品工業株式会社 | 新規キノリン置換化合物 |
| US9149471B2 (en) | 2013-09-30 | 2015-10-06 | National University Corporation Tokyo University Of Agriculture And Technology | Therapeutic agent for osteoporosis |
| ES2863586T3 (es) * | 2015-04-30 | 2021-10-11 | Taiho Pharmaceutical Co Ltd | Sal del ácido mesílico de un compuesto de aciltiourea, cristal de la misma y proceso para su producción |
| EP3973962A1 (en) | 2015-06-25 | 2022-03-30 | Taiho Pharmaceutical Co., Ltd. | Therapeutic agent for fibrosis |
| AU2017319260B2 (en) | 2016-08-31 | 2020-01-30 | Fujifilm Corporation | Anti-tumor agent, anti-tumor effect enhancer, and anti-tumor kit |
| JOP20190073A1 (ar) | 2016-10-31 | 2019-04-07 | Taiho Pharmaceutical Co Ltd | مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20 |
| EP3583943B1 (en) | 2017-02-15 | 2024-09-18 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition |
| US11701359B2 (en) | 2017-09-01 | 2023-07-18 | Taiho Pharmaceutical Co., Ltd. | Exon 18 and/or exon 21 mutant EGFR selective inhibitor |
| JP7074760B2 (ja) | 2017-09-08 | 2022-05-24 | 大鵬薬品工業株式会社 | 抗腫瘍剤及び抗腫瘍効果増強剤 |
| WO2019146130A1 (ja) | 2018-01-29 | 2019-08-01 | 富士フイルム株式会社 | 胆道がん用抗腫瘍剤および胆道がんの処置方法 |
| EP3766502A4 (en) | 2018-03-13 | 2021-05-05 | FUJIFILM Corporation | ANTITUMOR DRUG, ANTITUMOR ENHANCER AND ANTITUMOR KIT |
| US20210369739A1 (en) | 2018-09-18 | 2021-12-02 | Taiho Pharmaceutical Co., Ltd. | Combination therapy of acylthiourea compound and abiraterone |
| TWI872203B (zh) * | 2020-02-14 | 2025-02-11 | 日商大鵬藥品工業股份有限公司 | 醯基硫脲化合物的製造方法 |
| CN117820332B (zh) * | 2024-03-04 | 2024-05-14 | 烟台大学 | 苯并噻吩-硫脲类化合物及其制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002032872A1 (fr) * | 2000-10-20 | 2002-04-25 | Eisai Co., Ltd. | Composes a noyau aromatique azote |
| CA2603748A1 (en) * | 2005-04-06 | 2006-10-12 | Exelixis, Inc. | C-met modulators and methods of use |
| JP5399926B2 (ja) * | 2008-01-29 | 2014-01-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管阻害物質とタキサンとの併用 |
| JP2011513427A (ja) * | 2008-03-06 | 2011-04-28 | ジェネンテック, インコーポレイテッド | c−met及びEGFRアンタゴニストの併用療法 |
| DK2287155T3 (da) * | 2008-04-10 | 2013-07-29 | Taiho Pharmaceutical Co Ltd | Acylthiourea-forbindelse eller salt deraf samt anvendelse deraf |
| UY31800A (es) | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
| JP5699075B2 (ja) * | 2008-05-14 | 2015-04-08 | アムジエン・インコーポレーテツド | 癌の治療のためのvegf(r)阻害剤および肝細胞増殖因子(c−met)阻害剤との組合せ |
| US20100297075A1 (en) * | 2009-02-12 | 2010-11-25 | Arqule, Inc. | Combinational compositions and methods for treatment of cancer |
-
2012
- 2012-12-26 TW TW101150217A patent/TWI594986B/zh active
- 2012-12-27 ES ES12863476T patent/ES2717898T3/es active Active
- 2012-12-27 KR KR1020147016594A patent/KR101668931B1/ko active Active
- 2012-12-27 JP JP2013551770A patent/JP5852678B2/ja active Active
- 2012-12-27 PL PL12863476T patent/PL2799070T3/pl unknown
- 2012-12-27 EP EP12863476.3A patent/EP2799070B1/en active Active
- 2012-12-27 RU RU2014131058/04A patent/RU2589713C2/ru active
- 2012-12-27 DK DK12863476.3T patent/DK2799070T3/en active
- 2012-12-27 WO PCT/JP2012/083794 patent/WO2013100014A1/ja not_active Ceased
- 2012-12-27 HU HUE12863476A patent/HUE043991T2/hu unknown
- 2012-12-27 PT PT12863476T patent/PT2799070T/pt unknown
- 2012-12-27 US US14/369,060 patent/US20140378409A1/en not_active Abandoned
- 2012-12-27 AU AU2012361581A patent/AU2012361581B2/en active Active
-
2016
- 2016-06-16 AU AU2016204054A patent/AU2016204054A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2717898T3 (es) | 2019-06-26 |
| AU2012361581B2 (en) | 2016-06-30 |
| KR20140096375A (ko) | 2014-08-05 |
| TW201331182A (zh) | 2013-08-01 |
| US20140378409A1 (en) | 2014-12-25 |
| EP2799070B1 (en) | 2019-02-13 |
| JPWO2013100014A1 (ja) | 2015-05-11 |
| EP2799070A1 (en) | 2014-11-05 |
| TWI594986B (zh) | 2017-08-11 |
| AU2016204054A1 (en) | 2016-07-07 |
| AU2012361581A1 (en) | 2014-07-24 |
| KR101668931B1 (ko) | 2016-10-24 |
| RU2589713C2 (ru) | 2016-07-10 |
| PT2799070T (pt) | 2019-04-03 |
| DK2799070T3 (en) | 2019-04-23 |
| RU2014131058A (ru) | 2016-02-20 |
| HUE043991T2 (hu) | 2019-09-30 |
| WO2013100014A1 (ja) | 2013-07-04 |
| JP5852678B2 (ja) | 2016-02-03 |
| EP2799070A4 (en) | 2015-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2691417T4 (en) | Antistof fc-varianter | |
| HUE043991T2 (hu) | Hatáspotenciáló szer tumorellenes szerek számára | |
| SG10201601802YA (en) | Dispiropyrrolidine derivatives | |
| GB201109414D0 (en) | Diathermy -ionisation technique | |
| EP2787386A4 (en) | MASK | |
| IL247640A0 (en) | History of heteroaryl piperidine | |
| AP2014007621A0 (en) | 2-Thiopyrimidinones | |
| ZA201403050B (en) | R(+)-n-methyl-propargyl-aminoindan | |
| PL2543408T3 (pl) | Maska do wspomagania oddychania | |
| EP2691581A4 (en) | joint assembly | |
| HUE036188T2 (hu) | Egy imidazooxazin vegyületet tartalmazó tumorellenes hatás potenciátor | |
| ZA201403043B (en) | R(+)-n-formyl-propargyl-aminoindan | |
| SI2766342T1 (sl) | Derivati fenil-gvanidina | |
| ZA201308049B (en) | 3-ureidoisoquinolin-8-yl derivatives | |
| IL216134A0 (en) | Polygraph | |
| AU5031P (en) | BESYS Beschorneria yuccoides | |
| AU5171P (en) | Sunparamiho Mandevilla xamabilis | |
| AU4540P (en) | BUNNAN Baloskion tetraphyllum | |
| AU5026P (en) | Goldstrike Agapanthus inapertus | |
| GB201114668D0 (en) | Masking means | |
| GB201114015D0 (en) | Lock-through slit | |
| GB201100370D0 (en) | Concept seven | |
| GB201117537D0 (en) | Citizen-activated-police-response citizen activated-emergency-response | |
| AU337485S (en) | Cabin | |
| ZA201209319B (en) | Cyclopropyl-indole derivatives |